Clinical Impact of New Data From Boston 2016

November 11-15, 2016; Boston, Massachusetts
In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File Size: 581 KB
Released: November 30, 2016

Acknowledgements

Educational grant provided by:
Merck & Co., Inc.
Gilead Sciences
AbbVie

Related Content

Clinical Care Options (CCO) expert analysis by Prof Stefan Zeuzem on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Expert selections of important viral hepatitis data from EASL 2022, including studies of patients with HBV, HDV (hepatitis delta virus), and HCV, from Clinical Care Options (CCO)

Tarik Asselah, MD, PhD Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) podcast with Prof Stefan Zeuzem on key viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) podcast with Dr Nancy Reau on exciting viral hepatitis data from EASL, including HBV, HDV (hepatitis delta), and HCV

Nancy Reau, MD Released: July 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings